Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (253)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Alectinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Alectinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Almonertinib (Furmonertinib) |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Almonertinib (Furmonertinib)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Anlotinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Anlotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Apatinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Apatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
APG-115 (Alrizomadlin) |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
APG-115 (Alrizomadlin)
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
APG-2575 (Lisaftoclax) |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
APG-2575 (Lisaftoclax)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
ARV-110 (Bavdegalutamide) |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
ARV-110 (Bavdegalutamide)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
ARV-471 (Vepdegestrant) |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
ARV-471 (Vepdegestrant)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
Avapritinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Avapritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Avutometinib |
RAF/MEK Clamp | Solid Tumour | ||
|
Molecule
Avutometinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAF/MEK Clamp |
||||
Axitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Axitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Bavdegalutamide |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
Bavdegalutamide
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
AlectinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
Almonertinib (Furmonertinib)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
AnlotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
ApatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
APG-115 (Alrizomadlin)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
APG-2575 (Lisaftoclax)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
ARV-110 (Bavdegalutamide)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
ARV-471 (Vepdegestrant)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
AvapritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
AvutometinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAF/MEK Clamp |
|
AxitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
BavdegalutamideTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|